400828-91-3

Basic information

• Product Name: tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate;tert-butyl 4-(2,3-dihydro-1H-indol-1-yl)piperidine-1-carboxylate
• CAS NO: 400828-91-3
• Molecular Formula: C18H26N2O2
• Molecular Weight: 302.41124
• Mol File: 400828-91-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate(400828-91-3)
• EPA Substance Registry System: tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate(400828-91-3)

Safety Data

• Hazardous Substances Data: 400828-91-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
Tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate is utilized as a GRK5 inhibitor for its potential role in modulating receptor signaling pathways. This makes it a valuable tool in the development of new therapeutic agents targeting various diseases and conditions where GRK5 activity is implicated.
Used in Medicinal Chemistry:
As a compound with a unique structure and functional groups, tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate serves as a starting point for the synthesis of novel compounds with potential medicinal properties. Its indoline and tert-butyl ester groups can be modified to explore new chemical entities with improved pharmacological profiles.
Used in Drug Discovery:
tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate's potential as a GRK5 inhibitor highlights its utility in drug discovery, where it can be further optimized to enhance its potency, selectivity, and pharmacokinetic properties. This may lead to the development of new drugs targeting GRK5-related diseases and conditions.
Used in Biological Research:
Tert-butyl 4-(indolin-1-yl)piperidine-1-carboxylate can be employed in biological research to study the role of GRK5 in cellular processes and disease mechanisms. This may provide insights into the development of targeted therapies and a better understanding of the underlying biology of various diseases.

Upstream product

• 496-15-1 1-indoline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 1443247-65-1 4-(indolin-1-yl)-N-(3-(methylcarbamoyl)phenyl)piperidine-1-carboxamide 
• 401565-86-4 tert-butyl 4-(5-bromoindolin-1-yl)piperidine-1-carboxylate 
• 616898-64-7 oxo-[1-(1-pyridin-2-ylmethyl-piperidin-4-yl)-1H-indol-3-yl]-oxo-acetic acid methyl ester 
• 170364-57-5 enzastaurin 
• 594827-31-3 1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indole 
• 118511-81-2 1-(4-piperidinyl)-1H-indole 
• 170364-89-3 4-(indol-1-yl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models

A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson'

ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to heterocyclic compounds of Formula F-I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compositions comprising such compounds.

PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS

The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.

PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS

The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson' s disease.

MULTIVALENT RAS BINDING COMPOUNDS

Described herein are compounds that modulate Ras signaling, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with altered Ras signaling. Further described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds and methods of using such compounds in the treatment of cell proliferative disorders, including cancer.

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: Part 2. Pyridazine-based analogs

Design, synthesis, and biological evaluation of pyridazine-based, 4-bicyclic heteroaryl-piperidine derivatives as potent stearoyl-CoA desaturase-1 (SCD1) inhibitors are described. In a chronic study of selected analog (3e) in Zucker fa/fa (ZF) rat, dose-dependent decrease of body weight gain and plasma fatty acid desaturation index (DI) in both C16 and C18 are also demonstrated. The results indicate that the plasma fatty acid DI may serve as an indicator for direct target engagement and biomarker for SCD1 inhibition.

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: Urea-based analogs

A new series of urea-based, 4-bicyclic heteroaryl-piperidine derivatives as potent SCD1 inhibitors is described. The structure-activity relationships focused on bicyclic heteroarenes and aminothiazole-urea portions are discussed. A trend of dose-dependent decrease in body weight gain in diet-induced obese (DIO) mice is also demonstrated.

Discovery of a potent, orally bioavailable and highly selective human neuronal nitric oxide synthase (nNOS) inhibitor, N-(1-(piperidin-4-yl)indolin-5- yl)thiophene-2-carboximidamide as a pre-clinical development candidate for the treatment of migraine

We recently reported a series of 1,6-disubstituted indoline-based thiophene amidine compounds (5) as selective neuronal nitric oxide synthase (nNOS) inhibitors to mitigate the cardiovascular liabilities associated with hERG K+ channel inhibition (IC50 = 4.7 μM) with previously reported tetrahydroquinoline-based selective nNOS inhibitors (4). The extended structure-activity relationship studies within the indoline core led to the identification of 43 as a selection candidate for further evaluations. The in vivo activity in two different pain (spinal nerve ligation and migraine pain) models, the excellent physicochemical and pharmacokinetic properties, oral bioavailability (Fpo = 91%), and the in vitro safety profile disclosed in this report make 43 an ideal candidate for further evaluation in clinical applications related to migraine pain.

1-PIPERIDINYL-6-PIPERIDINYLSULFONYLINDOLES AS 5-HT (2B) RECEPTOR ANTAGONISTS

The present invention relates to novel indole derivatives which bind to the 5-HT2B receptor and are capable of interfering with the effects of 5-hydroxytryptamine (5-HT) at the 5-HT2B receptor; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy.

NOVEL COMPOUNDS

The present invention relates to novel indoline derivatives which bind to the 5-HT2B receptor and are capable of interfering with the effects of 5-hydroxytryptamine (5-HT) at the 5-HT2B receptor; to processes for their preparation; to pharmaceutical compositions containing them; and to the use of such compounds in therapy.